141 related articles for article (PubMed ID: 31664777)
1. Eyelashes depigmentation following treatment with pazopanib for metastatic renal cell carcinoma.
Vaccaro M; Riso G; Altavilla D; Cannavò SP
Dermatol Ther; 2019 Nov; 32(6):e13140. PubMed ID: 31664777
[No Abstract] [Full Text] [Related]
2. [Abnormal hair].
Coen M; Cramer B; Serratrice J
Rev Med Interne; 2019 Feb; 40(2):134-135. PubMed ID: 29054584
[No Abstract] [Full Text] [Related]
3. The Role of Pazopanib in Non-Clear Cell Renal Cell Carcinoma: A Systematic Review.
Sneed GT; Lee S; Brown JN; Hammond JM
Clin Genitourin Cancer; 2019 Dec; 17(6):419-424. PubMed ID: 31585694
[TBL] [Abstract][Full Text] [Related]
4. Impact of concomitant acid suppressive therapy on pazopanib efficacy and dose reductions in patients with metastatic renal cell carcinoma.
Van De Sijpe G; Beuselinck B; Van Nieuwenhuyse T; Poncelet R; Bechter O; Albersen M; Roussel E; Baldewijns M; Tack J; Spriet I
Eur J Clin Pharmacol; 2020 Sep; 76(9):1273-1280. PubMed ID: 32474662
[TBL] [Abstract][Full Text] [Related]
5. Changes in skeletal muscle area and lean body mass during pazopanib vs sunitinib therapy for metastatic renal cancer.
Köstek O; Yılmaz E; Hacıoğlu MB; Demircan NC; Gökyer A; Uzunoğlu S; Tunçbilek N; Çiçin İ; Erdoğan B
Cancer Chemother Pharmacol; 2019 Apr; 83(4):735-742. PubMed ID: 30680522
[TBL] [Abstract][Full Text] [Related]
6. Pazopanib outscores sunitinib on tolerability.
Cancer Discov; 2014 Jan; 4(1):OF8. PubMed ID: 24402960
[TBL] [Abstract][Full Text] [Related]
7. Cardiac metastasis from renal cell carcinoma successfully treated with pazopanib: impact of TKIs' antiangiogenic activity.
Schinzari G; Monterisi S; Signorelli D; Cona MS; Cassano A; Danza F; Barone C
Tumori; 2014; 100(6):e298-300. PubMed ID: 25688515
[TBL] [Abstract][Full Text] [Related]
8. Exploratory Investigation of Target Pazopanib Concentration Range for Patients With Renal Cell Carcinoma.
Noda S; Yoshida T; Hira D; Murai R; Tomita K; Tsuru T; Kageyama S; Kawauchi A; Ikeda Y; Morita SY; Terada T
Clin Genitourin Cancer; 2019 Apr; 17(2):e306-e313. PubMed ID: 30598361
[TBL] [Abstract][Full Text] [Related]
9. Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma.
Sternberg CN; Donskov F; Haas NB; Doehn C; Russo P; Elmeliegy M; Baneyx G; Banerjee H; Aimone P; Motzer RJ
Clin Cancer Res; 2018 Jul; 24(13):3005-3013. PubMed ID: 29330204
[No Abstract] [Full Text] [Related]
10. Severe pazopanib-induced hepatotoxicity: clinical and histologic course in two patients.
Klempner SJ; Choueiri TK; Yee E; Doyle LA; Schuppan D; Atkins MB
J Clin Oncol; 2012 Sep; 30(27):e264-8. PubMed ID: 22802316
[No Abstract] [Full Text] [Related]
11. Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features.
Kim JH; Park I; Lee JL
Cancer Chemother Pharmacol; 2016 Aug; 78(2):325-32. PubMed ID: 27324136
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes and toxicities of pazopanib administered orally in crushed form: Case reports and review of the literature.
Stein J; Milhem M; Vaena D
J Oncol Pharm Pract; 2020 Jan; 26(1):232-235. PubMed ID: 30961437
[TBL] [Abstract][Full Text] [Related]
13. Good tolerability, long-term survival and easy management of side effects in a patient with metastatic renal cell carcinoma treated with pazopanib.
Frascaroli M; Di Cesare P
Tumori; 2014; 100(6):e301-4. PubMed ID: 25688516
[TBL] [Abstract][Full Text] [Related]
14. Pazopanib: an oral multitargeted tyrosine kinase inhibitor for use in renal cell carcinoma.
LaPlant KD; Louzon PD
Ann Pharmacother; 2010 Jun; 44(6):1054-60. PubMed ID: 20407031
[TBL] [Abstract][Full Text] [Related]
15. Leg ulcers associated with cutaneous vascular degeneration in a patient receiving pazopanib chemotherapy.
Hioki T; Takama H; Makita S; Chen KR; Watanabe D; Akiyama M
Eur J Dermatol; 2017 Oct; 27(5):546-547. PubMed ID: 29084643
[No Abstract] [Full Text] [Related]
16. Pazopanib- and bevacizumab-induced reversible heart failure in a patient with metastatic renal cell carcinoma: A case report.
Abdallah AO; Vallurupalli S; Kunthur A
J Oncol Pharm Pract; 2016 Jun; 22(3):561-5. PubMed ID: 25956420
[No Abstract] [Full Text] [Related]
17. Assessing Outcomes and Prognostic Factors for First-Line Therapy in Elderly Patients With Metastatic Renal Cell Carcinoma: Real-Life Data From a Single United Kingdom Institution.
Uccello M; Alam T; Abbas H; Nair A; Paskins J; Faust G
Clin Genitourin Cancer; 2019 Jun; 17(3):e658-e663. PubMed ID: 31000484
[TBL] [Abstract][Full Text] [Related]
18. Posterior Reversible Encephalopathy Syndrome With Concurrent Nephrotic Syndrome in a Patient Treated With Pazopanib for Metastatic Renal Cell Carcinoma: Case Report and Review of the Literature.
Miaris N; Maltezou M; Papaxoinis G; Visvikis A; Samantas E
Clin Genitourin Cancer; 2017 Feb; 15(1):e99-e103. PubMed ID: 27601362
[No Abstract] [Full Text] [Related]
19. Severe hyperglycaemia following pazopanib treatment: The role of drug-drug-gene interactions in a patient with metastatic renal cell carcinoma-A case report.
Kuruc Poje D; Božina N; Šimičević L; Žabić I
J Clin Pharm Ther; 2020 Aug; 45(4):628-631. PubMed ID: 32369219
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin Inhibitors as Treatment of Sunitinib/Pazopanib-induced Hypertension in Metastatic Renal Cell Carcinoma.
Penttilä P; Rautiola J; Poussa T; Peltola K; Bono P
Clin Genitourin Cancer; 2017 Jun; 15(3):384-390.e3. PubMed ID: 28089721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
